Journal
CELLS
Volume 8, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/cells8050439
Keywords
ALM; hypoxia; HIF-1; inhibitor; mTOR; combination therapy
Categories
Funding
- National Natural Science Foundation of China [81702361, 81874060]
Ask authors/readers for more resources
HIF-1 serves as an important regulator in cell response to hypoxia. Due to its key role in promoting tumor survival and progression under hypoxia, HIF-1 has become a promising target of cancer therapy. Thus far, several HIF-1 inhibitors have been identified, most of which are from synthesized chemical compounds. Here, we report that ALM (ActinoLactoMycin), a compound extracted from metabolites of Streptomyces flavoretus, exhibits inhibitory effect on HIF-1. Mechanistically, we found that ALM inhibited the translation of HIF-1 protein by suppressing mTOR signaling activity. Treatment with ALM induced cell apoptosis and growth inhibition of cancer cells both in vitro and in vivo in a HIF-1 dependent manner. More interestingly, low dose of ALM treatment enhanced the anti-tumor effect of Everolimus, an inhibitor of mTOR, suggesting its potential use in combination therapy of tumors, especially solid tumor patients. Thus, we identified a novel HIF-1 inhibitor from the metabolites of Streptomyces flavoretus, which shows promising anti-cancer potential.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available